Department of Physics, School of Advanced Sciences, Vellore Institute of Technology, Chennai - 600 127, India.
Department of Radiotherapy, Sri Shankara Cancer Hospital & Research Centre, Bangalore - 560 004, India.
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1425-1432. doi: 10.31557/APJCP.2024.25.4.1425.
This study comprehensively investigated pre-treatment quality assurance (QA) for 100 cancer patients undergoing stereotactic treatments (SRS/SRT) using various detectors.
The study conducted QA for SRS/SRT treatments planned with a 6MV SRS beam at a dose rate of 1,000 MU/min, utilizing Eclipse v13.6 Treatment Planning System (TPS). Point dose measurements employed 0.01cm3 and 0.13cm3 cylindrical ionization chambers, while planar dose verification utilized Gafchromic EBT-XD Film and Portal Imager (aS1000). Plans were categorized by target volume, and a thorough analysis compared point dose agreements, planar dose gamma pass rates, and their correlations with chamber volume mean dose, detector type, and point dose agreement. Additionally, the consistency between different ionization chambers was assessed.
Point dose agreement generally improved with increasing target volume, except for volumes over 10cm3 with 0.01cm3 chambers, showing a contrary trend. Significant differences (p<0.05) were observed between TPS and measured doses for both chambers. Gamma pass rate improved with increasing target volume in EBT XD and aS1000 analyses, except for the >10cm3 group in EBT XD. EBT XD demonstrated better agreement with TPS for target volumes up to 10cm3 compared to aS1000, with a statistically significant difference (p<0.05) between the detectors. Strong correlations were found between chamber point dose and chamber volume mean dose agreement, as well as between the two gamma criteria analyses of the same detector type in the planar dose correlation analysis. However, weak correlations were discovered for other analyses.
This study found weak correlation between different detector types in pre-treatment QA for point dose and planar dose evaluation. However, within a specific detector type, strong correlation was observed for different point dose evaluation methods and gamma criteria. This highlights the importance of cautious interpretation of QA results, particularly for SRS QA, due to the lack of correlation between detector types.
本研究全面调查了 100 例接受立体定向治疗(SRS/SRT)的癌症患者的治疗前质量保证(QA),使用了各种探测器。
本研究使用剂量率为 1000MU/min 的 6MV SRS 束,在 Eclipse v13.6 治疗计划系统(TPS)上对 SRS/SRT 计划进行 QA。点剂量测量使用 0.01cm3 和 0.13cm3 圆柱形电离室,而平面剂量验证则使用 Gafchromic EBT-XD 胶片和 Portal Imager(aS1000)。计划根据靶区体积进行分类,并对点剂量一致性、平面剂量伽马通过率及其与腔室体积平均剂量、探测器类型和点剂量一致性的相关性进行了全面分析。此外,还评估了不同电离室之间的一致性。
点剂量一致性随着靶区体积的增加而提高,除了 0.01cm3 腔室的 10cm3 以上体积外,呈相反趋势。对于两个腔室,TPS 和测量剂量之间都存在显著差异(p<0.05)。EBT XD 和 aS1000 分析中的伽马通过率随着靶区体积的增加而提高,除了 EBT XD 的>10cm3 组外。与 aS1000 相比,EBT XD 在靶区体积达 10cm3 以下时与 TPS 的一致性更好,且两种探测器之间存在统计学显著差异(p<0.05)。在平面剂量相关性分析中,腔室点剂量与腔室体积平均剂量一致性以及同一探测器类型的两种伽马标准分析之间存在很强的相关性。然而,在其他分析中发现了较弱的相关性。
本研究发现,在点剂量和平面剂量评估的治疗前 QA 中,不同探测器类型之间相关性较弱。然而,在特定的探测器类型中,不同的点剂量评估方法和伽马标准之间存在很强的相关性。这突出表明,由于缺乏探测器类型之间的相关性,对 QA 结果的解释需要谨慎。